The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis
Abstract
Background The incidence of hepatocellular carcinoma (HCC) has increased significantly in United States over the last few decades in parallel with the epidemic of nonalcoholic fatty liver disease (NAFLD). Limited data suggests that HCC could arise in steatotic liver without the presence of cirrhosis. The present study was conducted to characterize patients with NAFLD presenting with HCC in non-cirrhotic liver (NCL) compared to the NAFLD- HCC patients in association with cirrhotic liver (CL).Methods A retrospective analysis of all patients diagnosed with HCC and NAFLD diagnosis seen at our institution between 2003 and 2012 was done. The patients were characterized based on demographic and clinical variables as well as histological and tumor features. Comparisons between the NCL and CL groups were done using analysis of variance (ANOVA) or the non-parametric Kruskal-Wallis tests and Pearson's chi-square tests or Fisher's Exact tests as appropriate. P value of <0.05 was considered statistically significant.Results Thirty-six patients with NAFLD and HCC in NCL (HCC-NCL group) were identified and compared to 47 patients with NAFLD-HCC and Liver Cirrhosis (HCC-LC group). Liver fibrosis was not present in 55.9 % of patients in the HCC-NCL group (F0), stage 1 was present in 17.6 %, stage 2 in 8.8 % and stage 3 in 17.6 %. Lobular inflammation was present in 63.6 % of non-cirrhotic patients. Patients in the HCC-NCL were older (67.5 ± 12.3 vs. 62.7 ± 8.1 years), and less likely to be obese (52 % vs. 83 %) or have type 2 diabetes (38 % vs. 83 %), with p value <0.05 for all. More importantly, compared with the HCC-CL group, those in the HCC-NCL group were more likely to present with a single nodule (80.6 % vs. 52.2 %), larger nodule size (>5 cm) (77.8 % vs. 10.6 %), and receive hepatic resection as the modality of HCC treatment (66.7 % vs. 17 %); and were less likely to receive loco-regional therapy (22.3 % vs. 61.7 %) or orthotopic liver transplantation (OLT) (0 % vs. 72.3 %), with p value <0.001 for all. Furthermore, 86 % of patients without cirrhosis had HCC recurrence compared to only 14 % in patients with cirrhosis (p < 0.001). Unadjusted analysis indicates that non-cirrhotics had worse survival with mortality rate of 47 % vs. 28 % in CL group (p = 0.03); however this difference in survival between two groups was not significant after adjusting for age or OLT (p > 0.05).Conclusion Patients with HCC in the absence of liver cirrhosis are more likely to present at an older age with larger tumor and have higher rates of tumor recurrence. Studies to assess the cost-effectiveness of HCC surveillance in this group should be conducted.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a retrospective analysis of individuals with MASLD who were diagnosed with HCC between 2003 and 2012, those with HCC on a non-cirrhotic liver more frequently had a larger nodule size and/or a greater rate of HCC recurrence than those with cirrhosis. 235”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [235]
Citations
Cites
Jemal, A., Bray, F., Ferlay, J., Ward, E., & Forman, D. (2011) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 55,077
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Management of Hepatocellular Carcinoma: An Update Δσ
Bruix, J., & Sherman, M. (2011) · Hepatology · doi:10.1002/hep.24199 · Cited by 8,135
Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis
El‐Serag, H. B., & Rudolph, K. L. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.061 · Cited by 5,484
El-Serag, H. B. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1001683 · Cited by 3,529
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890
Williams, C. D., Stengel, J. Z., Asike, M., Torres, D. M., Shaw, J. C., Contreras, M., Landt, C. L., & Harrison, S. A. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.09.038 · Cited by 2,182
Waist circumference as a measure for indicating need for weight management
Lean, M. E. J., Han, T. S., & Morrison, C. E. (1995) · BMJ · doi:10.1136/bmj.311.6998.158 · Cited by 1,869
Altekruse, S. F., McGlynn, K. A., & Reichman, M. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7753 · Cited by 1,695
Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma: A Weighty Connection
Starley, B. Q., Calcagno, C. J., & Harrison, S. A. (2010) · Hepatology · doi:10.1002/hep.23594 · Cited by 1,349
Cited by
Sorted by citations
Items 101–166 of 166
Biomarker Discovery in Liver Disease Using Untargeted Metabolomics in Plasma and Saliva
Daniels, N. J., Hershberger, C., Kerosky, M., Wehrle, C., Raj, R., Aykun, N., Allende, D. S., Aucejo, F., & Rotroff, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251810144 · Cited by 8
Self-citationRodriguez, N. S., & Hartmann, P. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100058 · Cited by 10
Meng, Z., Qiu, X., Chen, Z., Lee, Y.-T., Zhou, L., Lu, Y., Liu, T., Li, S., Lévi, B., Gallagher, K. A., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101488 · Cited by 7
Fu, Y., Bonifacio-Mundaca, J., Desterke, C., Casafont, Í., & Mata-Garrido, J. (2025) · Genes · doi:10.3390/genes16080920 · Cited by 7
Das, J., Barman, B., Sarma, P., Das, B. K., Chetia, R., & Kalita, P. P. (2025) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2025.102403 · Cited by 8
Barrett, R., Archer, A. J., Cathcart, J., Abeysekera, K. W. M., Dillon, J. F., & Brennan, P. (2026) · Liver International · doi:10.1111/liv.70511 · Cited by 6
Wang, L., Liu, K., Deng, L., Zhou, G., Qian, W., & Xu, K. (2023) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-023-04694-5 · Cited by 6
Kowada, A. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-080549 · Cited by 7
Nutritional and Dietary Interventions for Nonalcoholic Fatty Liver Disease
Cai, C. X., Carlos, S., Solaimani, P., Trivedi, B. J., Tran, C. T., & Castelino‐Prabhu, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814466-4.00029-x · Cited by 6
Nagra, N. K., Penna, R., Selva, D. L., Coy, D. L., Siddique, A., & Burman, B. E. (2021) · Journal of Clinical and Translational Research · doi:10.18053/jctres.07.202105.009 · Cited by 6
Evaluation of the Patient with Markedly Abnormal Liver Enzymes
Reutemann, B. A., & Gordon, F. D. (2022) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.08.007 · Cited by 6
Cox, B., Trasolini, R. P., Galts, C., Yoshida, E. M., & Marquez, V. (2021) · Canadian Liver Journal · doi:10.3138/canlivj-2021-0004 · Cited by 6
Hepatocellular Carcinoma: the Impact of NAFLD
Allaire, M., Dupont, B., Nahon, P., Ganne-Carrié, N., & Nault, J. (2016) · Current Hepatology Reports · doi:10.1007/s11901-016-0303-0 · Cited by 3
Dong, Y., Cheng, J., Huang, Y., Qiu, Y., Cao, J.-Y., Lu, X.-Y., Wang, W., Möller, K., & Dietrich, C. F. (2025) · ULTRASONOGRAPHY · doi:10.14366/usg.24205 · Cited by 5
Analyzing TCGA Data to Identify Gene Mutations Linked to Hepatocellular Carcinoma in Asians
Kim, T., Issa, D., & Onyshchenko, M. I. (2022) · Gastrointestinal Tumors · doi:10.1159/000524576 · Cited by 5
Self-citationZhang, K.-J., Ye, T., Lu, W., Xu, F., Xie, Y.-M., Wang, D.-D., Xiao, Z., Liu, S., Yao, W.-F., Cheng, J., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1042869 · Cited by 5
NASH/NAFLD-Related Hepatocellular Carcinoma: An Added Burden
Georgescu, D., Lighezan, D., Rosca, C. I., Nistor, D., Ancusa, O., Suceava, I., Iancu, M. A., & Kundnani, N. R. (2023) · Life · doi:10.3390/life14010025 · Cited by 6
Peretinoin as an adjuvant therapy for hepatocellular carcinoma
Tan, C.-K. (2016) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2016.1238303 · Cited by 5
O-GlcNAcylation: Undesired tripmate but an opportunity for treatment in NAFLD-HCC
Santos‐Laso, Á., Perugorria, M. J., & Bañales, J. M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.04.027 · Cited by 5
Haam, J.-H., Lee, Y. K., Suh, E., & Kim, Y. (2022) · Diagnostics · doi:10.3390/diagnostics12051199 · Cited by 4
Zhang, W., Zhao, Y., He, Q., & Lang, R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1211126 · Cited by 4
Mărginean, C. O., Meliţ, L. E., & Săsăran, M. O. (2021) · Applied Sciences · doi:10.3390/app11073240 · Cited by 4
Sexual Dimorphisms in Nonalcoholic Fatty Liver Disease
Musto, J., Spengler, E. K., & German, M. N. (2021) · Current Hepatology Reports · doi:10.1007/s11901-021-00568-8 · Cited by 4
Characteristics and survival of hepatocellular carcinoma in non-cirrhotic liver.
Romero-Gutiérrez, M., Tercero, M. A., Martín, J. R., Limo, J. D. C., Varasa, T. D. A., de Frutos, C. G., Pérez, G., Sánchez‐Ruano, J. J., Moreno, A. Z. G., & Rodríguez, R. G. (2019) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2019.6180/2018 · Cited by 4
Evolution of transplant oncology indications: a single-institution experience over 40 years
Lai, Q., Parisse, S., Corradini, S. G., Ferri, F., Kolovou, K., Campagna, P., Melandro, F., Mennini, G., Merli, M., & Rossi, M. (2024) · Updates in Surgery · doi:10.1007/s13304-024-01827-1 · Cited by 3
Zerehpooshnesfchi, S., Safri, F., Pan, Z., Nguyen, R., Yuen, L., Lam, V. W.-T., Nahm, C. B., Pang, T., Ahlenstiel, G., George, J., et al. (2025) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223251339402 · Cited by 3
Steatotic liver disease: what role does alcohol consumption play?
Testino, G., Fucile, C., Gnocchi, M., Rosa, G. M., & Caputo, F. (2025) · Minerva Medica · doi:10.23736/s0026-4806.25.09726-5 · Cited by 3
NAFLD-Associated Hepatocellular Carcinoma: a Threat to Patients with Metabolic Disorders
Sasdelli, A., Brodosi, L., & Marchesini, G. (2016) · Current Hepatology Reports · doi:10.1007/s11901-016-0297-7 · Cited by 3
Croatian guidelines for the diagnosis and treatment of nonalcoholic fatty liver disease
Jukić, L. V. (2021) · Acta Clinica Croatica · doi:10.20471/acc.2021.60.s1.03 · Cited by 3
SEER-based risk stratification system for patients with primary non-cirrhotic liver cancer
Cao, R., Jiang, H., Liang, G., & Zhang, W. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05057-7 · Cited by 3
Lee, C.-H., Kang, M.-G., Oh, S., Gwak, I. S., Shen, C., Oh, H., Park, Y. R., Kim, J. S., & Park, J. H. (2025) · Clinics And Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2025.102612 · Cited by 3
Epidemiology of hepatocellular carcinoma in nonalcoholic fatty liver disease
Moriguchi, M., Seko, Y., Takahashi, A., & Itoh, Y. (2019) · Hepatoma Research · doi:10.20517/2394-5079.2019.20 · Cited by 4
Hepatocellular Carcinoma Screening and Nonalcoholic Fatty Liver Disease: How is it Different?
Acharya, S., & Bopanna, S. (2020) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2020.04.004 · Cited by 3
Helvacı, B. C., Tam, A. A., Erdoğan, B. T., Fakı, S., Çuhacı, F. N., Topaloğlu, O., Ersoy, R., & Çakır, B. (2025) · Archives of Medical Science · doi:10.5114/aoms/204182 · Cited by 2
Nutraceuticals for Non-alcoholic Fatty Liver Disease
Sonmez, A., Ercin, C., Cesur, M., & Doğru, T. (2021) · Contemporary cardiology · doi:10.1007/978-3-030-62632-7_9 · Cited by 2
Radu, P., Aeby, G., Schwacha-Eipper, B., Kolly, P., Mare, C., Banz, V., & Dufour, J. (2021) · Journal of Surgical Oncology · doi:10.31487/j.jso.2020.06.07
Comments on “NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis”
Li, G., Li, Y., Liu, J., & Zhao, H. (2016) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn.2016.12.02 · Cited by 2
Synchronous oesophageal and gastric sarcomatoid carcinoma: first reported case in Australia
Pateria, P., Muwanwella, N., Chai, M., & Venugopal, K. (2018) · BMJ Case Reports · doi:10.1136/bcr-2018-225092 · Cited by 2
Hepatocarcinoma en hígado no cirrótico: serie bicéntrica de 19 casos
Marcano, A. J. L., Martin, M. S., Ramia, J. M., Cano, A. P., Llamas, R. D. L. P., Berna, C. V., Guillén, J. R. O., & Requejo, A. (2019) · Revista Argentina de Cirugía · doi:10.25132/raac.v111.n4.1417.es · Cited by 1
Xiong, K.-G., Lin, T.-S., Lin, Q.-B., Kong, J., & Ke, K.-Y. (2025) · Egyptian Liver Journal · doi:10.1186/s43066-025-00416-0 · Cited by 1
Tan, Y. (2019) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2019.19.003308 · Cited by 1
Non-alcoholic Fatty Liver Disease and Hepatocellular Carcinoma…
Oh, H., & Jun, D. W. (2017) · Journal of Liver Cancer · doi:10.17998/jlc.17.2.117
Hepatocarcinoma and Non Alcoholic Fatty Liver Disease
Alves, R. C. P. (2019) · Advanced Research in Gastroenterology & Hepatology · doi:10.19080/argh.2019.14.555885
NAFLD, Hepatocellular Carcinoma, and Extrahepatic Cancers
Younes, R., & Bugianesi, E. (2020) · Springer eBooks · doi:10.1007/978-3-319-95828-6_10
Moctezuma‐Velázquez, C. (2021) · Revista de Gastroenterología de México (English Edition) · doi:10.1016/j.rgmxen.2020.05.005
Investigating Critical Risk Factors in Liver Cancer PredictionPreprint
Li, J., Tao, Y., & Cai, T. (2021) · arXiv (Cornell University) · doi:10.48550/arxiv.2102.02088
Moctezuma‐Velázquez, C. (2020) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2020.05.003
A Signature of Seven Lipid Metabolism Genes to Predict Hepatocellular Carcinoma PrognosisPreprint
Li, M., Wu, X., Liao, S., wang, S., lin, S., Song, Z., Peng, B., & Shen, S. (2021) · Research Square · doi:10.21203/rs.3.rs-468421/v1
Viral alcoholic and fatty liver diseases
Zigmond, E., & Shouval, D. (2021) · doi:10.1093/med/9780198816805.003.0074
Editorial: Targeting Thyroid Hormone-Dependent Pathways in Proliferative and Degenerative Disorders
Perra, A., & Plateroti, M. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.944769
Lipid droplets are intracellular mechanical stressors that promote hepatocyte dedifferentiationPreprint
Loneker, A. E., Alisafaei, F., Kant, A., Janmey, P. A., Shenoy, V. B., & Wells, R. G. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.27.505524
Rashad, N., Elshamy, A., Hussien, M., Elfarargy, O., El-Helaly, A. M., & Gomaa, A. (2022) · The Egyptian Journal of Hospital Medicine · doi:10.21608/ejhm.2022.270492
The Role of Microbiome in Nonalcoholic Fatty Liver Disease
Lee, H. W. (2023) · Springer eBooks · doi:10.1007/978-981-19-4492-5_7
Recent Updates in the Prevention of Nonalcoholic Fatty Liver Disease
El‐Kassas, M., Awad, A., & Méndez‐Sánchez, N. (2023) · Gene Expression · doi:10.14218/ge.2022.00005s
Machado, M. V. (2024) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-24-132
El‐Kassas, M., Barakat, E., Shousha, H. I., Kohla, M., Said, M., Mostafa, E. F., Tawheed, A., Shamkh, M. A. A., Nabil, M. M., Elkhateeb, E., et al. (2024) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002870
Hernáez, R., & Kanwal, F. (2025) · Springer eBooks · doi:10.1007/978-3-031-90225-3_3
Khare, T., Stuckel, A. J., Gupta, S., Liu, K., Hammoud, G. M., Ibdah, J. A., & Khare, S. (2025) · Cancers · doi:10.3390/cancers17193241
Intracardiac Mass Reveals Hepatocellular Carcinoma: A Rare Case of Cardiac Metastasis
Abdelrahman, T., Ali, M., Ahmed, A., & Rangarajan, H. (2025) · Cureus · doi:10.7759/cureus.97501
Hepatocellular Carcinoma in the Setting of Metabolic Dysfunction Associated Steatotic Liver Disease
Su, A., Clark, J. M., & Kim, A. K. (2026) · Current Hepatology Reports · doi:10.1007/s11901-025-00707-5
Wu, N., Xiong, X., Wang, X. Y., Wei, S., Shi, X., Chen, Y., Zhou, W., Wang, J., Zhang, L., Liu, B., et al. (2026) · Hepatology International · doi:10.1007/s12072-026-11107-2
Safri, F., Pickford, R., Xu, Y., Yang, W., Nguyen, R., Yuen, L., Lam, 。., Nahm, C. B., Pang, T., George, J., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27136060
Villani, R., & Serviddio, G. (2026) · Annals of Hepatology · doi:10.1016/j.aohep.2026.102434
BindingDB (2021) · UC San Diego · doi:10.7270/q2dj5jxg
Metadata
- Authors
- Mohamad, B., Shah, V., Onyshchenko, M., Elshamy, M., Aucejo, F., Lopez, R., Hanouneh, I. A., Alhaddad, R., & Alkhouri, N.
- Affiliations
- Cleveland Clinic (US)
- Corresponding author
- Alkhouri, Naim
- Venue
- Hepatology International
- Published
- 2015-11-11
- Volume
- 10
- Issue
- 4
- Pages
- 632-639
- ISSN
- 1936-0533 (ISSN-L)
- 1936-0541
- OpenAlex
- W2117454090
- Cited by
- 166
- References
- 35
- Citations by year
- 2026: 5 · 2025: 16 · 2024: 8 · 2023: 18 · 2022: 24 · 2021: 24 · 2020: 23 · 2019: 21 · 2018: 11 · 2017: 9 · 2016: 7
- FWCI
- 5.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Hepatology International (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- hepatocellular carcinoma, non-alcoholic fatty liver disease, non-cirrhotic liver, liver cirrhosis, liver fibrosis, lobular inflammation, hepatectomy, liver transplantation, survival outcomes, prognostic factors, obesity, type 2 diabetes
- MeSH terms
- Aged, Female, Carcinoma, Hepatocellular, Humans, Liver Cirrhosis, Liver Neoplasms, Male, Middle Aged, Neoplasm Recurrence, Local, Prognosis, Retrospective Studies, Risk Factors, Survival Analysis, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review